Asthma and COPD proteomics: Current approaches and future directions

Proteomics - Clinical Applications

Volumn 9, Issue 1-2, 2015, Pages 203-220

  Terracciano, Rosa ^a   Pelaia, Girolamo ^a   Preianò, Mariaimmacolata ^a   Savino, Rocco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Asthma; BALF; COPD; Induced sputum

Indexed keywords

ACUTE PHASE PROTEIN; CALGRANULIN A; CALGRANULIN B; CD163 ANTIGEN; COMPLEMENT FACTOR; CYTOKERATIN; CYTOKINE; EOSINOPHIL GRANULE PROTEIN; GLUCOSE REGULATED PROTEIN 78; HOUSE DUST ALLERGEN; PEROXIREDOXIN 1; PROLACTIN; BIOLOGICAL MARKER; PROTEOME;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALPHA 1 ANTITRYPSIN DEFICIENCY; ASTHMA; BLOOD ANALYSIS; BODY FLUID; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RHINOSINUSITIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; EPITHELIAL LINING FLUID; EXPIRED AIR; FORCED EXPIRATORY VOLUME; HUMAN; LUNG EMPHYSEMA; LUNG FLUID; MASS SPECTROMETRY; NON SMALL CELL LUNG CANCER; NOSE MUCUS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SMOKING; SPUTUM ANALYSIS; TWO DIMENSIONAL ELECTROPHORESIS; ANIMAL; METABOLISM; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANIMALS; ASTHMA; BIOLOGICAL MARKERS; HUMANS; PROTEOME; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84922823093     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400099     Document Type: Review

References (103)

1. Vestbo, J., Hurd, S. S., Agusti, A. G., Jones, P. W. et al., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease-GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013, 187, 347-365.
2. Croisant, S., Epidemiology of asthma: prevalence and burden of disease. Adv. Exp. Med. Biol. 2014, 795, 17-29.
3. Han, M. K., Agusti, A., Calverley, P. M., Celli, B. R. et al., Chronic obstructive pulmonary disease phenotypes: the future Of COPD. Am. J. Respir. Crit. Care Med. 2010, 182, 598-604.
4. Wenzel, S., Complex phenotypes in asthma: current definitions. Pulm. Pharmacol. Ther. 2013, 26, 710-715.
5. Cazzola, M., Segreti, A., Bettoncelli, G., Calzetta, L. et al., Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim. Care Respir. J. 2011, 20, 291-298.
6. Cazzola, M., Matera, M. G., Rogliani, P., Page, C., Treating systemic effects of COPD. Trends Pharmacol. Sci. 2007, 28, 544-550.
7. Papaiwannou, A., Zarogoulidis, P., Porpodis, K., Spyratos, D. et al., Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. J. Thorac. Dis. 2014, 6, S146-S151.
8. Terracciano, R., Preianò, M., Palladino, G. P., Carpagnano, G. E. et al., Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for non-invasive biomarker discovery of chronic inflammatory lung diseases. Proteomics 2011, 11, 3402-3414.
9. Pelaia, G., Terracciano, R., Vatrella, A., Gallelli, L. et al., Application of proteomics and peptidomics to COPD. Biomed Res. Int. 2014, 2014, 764581.
10. Bowler, R. P., Ellison, M. C., Reisdorph, N., Proteomics in pulmonary medicine. Chest 2006, 130, 567-574.
11. Pelaia, G., Vatrella, A., Maselli, R., The potential of biologics for the treatment of asthma. Nat. Rev. Drug Discov. 2012, 11, 958-972.
12. Barnes, P. J., New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat. Rev. Drug Discov. 2013, 12, 543-559.
13. Nicholas, B., Djukanović, R., Induced sputum: a window to lung pathology. Biochem. Soc. Trans. 2009, 37, 868-872.
14. Chen, H., Wang, D., Bai, C., Wang, X., Proteomics-based biomarkers in chronic obstructive pulmonary disease. J. Proteome Res. 2010, 9, 2798-2808.
15. Gharib, S. A., Nguyen, E. V., Lay, Y., Plampin, J. D. et al., Induced sputum proteome in healthy subjects and asthmatic patients. J. Allergy Clin. Immunol. 2011, 128, 1176-1184.
16. Lee, T. H., Jang, A. S., Park, J. S., Kim, T. H., Elevation of S100 calcium binding protein A9 in sputum of neutrophilic inflammation in severe uncontrolled asthma. Ann. Allergy Asthma Immunol. 2013, 111, 268-275.
17. Magi, B., Bini, L., Perari, M. G., Fossi, A. et al., Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis 2002, 23, 3434-3444.
18. Bargagli, E., Olivieri, C., Prasse, A., Bianchi, N. et al., Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Inflammation 2008, 31, 351-354.
19. Bargagli, E., Olivieri, C., Cintorino, M., Refini, R. M. et al., Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis?. Inflammation 2011, 34, 85-91.
20. Korthagen, N. M., Nagtegaal, M. M., van Moorsel, C. H., Kazemier, K. M. et al., MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. Clin. Exp. Immunol. 2010, 161, 342-347.
21. Hara, A., Sakamoto, N., Ishimatsu, Y., Kakugawa, T. et al., S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir. Med. 2012, 106, 571-580.
22. van Bon, L., Cossu, M., Loof, A., Gohar, F. et al., Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann. Rheum. Dis. 2014, 73, 1585-1589.
23. MacGregor, G., Gray, R. D., Hilliard, T. N., Imrie, M. et al., Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid. J. Cyst. Fibros. 2008, 7, 352-358.
24. Gray, R. D., MacGregor, G., Noble, D., Imrie, M. et al., Sputum proteomics in inflammatory and suppurative respiratory diseases. Am. J. Respir. Crit. Care Med. 2008, 178, 444-452.
25. Nicholas, B., Skipp, P., Mould, R., Rennard, S. et al., Shotgun proteomic analysis of human-induced sputum. Proteomics 2006, 6, 4390-4401.
26. Nicholas, B. L., Skipp, P., Barton, S., Singh, D. et al., Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010, 181, 1049-1060.
27. Ohlmeier, S., Mazur, W., Linja-Aho, A., Louhelainen, N. et al., Sputum proteomics identifies elevated PIGR levels in smokers and mild-to-moderate COPD. J. Proteome Res. 2012, 11, 599-608.
28. Casado, B., Iadarola, P., Pannell, L. K., Luisetti, L. K. et al., Protein expression in sputum of smokers and chronic obstructive pulmonary disease patients: a pilot study by CapLC-ESI-Q-TOF. J. Proteome Res. 2007, 6, 4615-4623.
29. Terracciano, R., Gaspari, M., Testa, F., Pasqua, L. et al., Selective binding and enrichment for low-molecular weight biomarker molecole in human plasma after exposure to nanoporous silica particles. Proteomics 2006, 6, 3243-3250.
30. Terracciano, R., Pasqua, L., Casadonte, F., Frascà, S. et al., Derivatized mesoporous silica beads for MALDI-TOF MS profiling of human plasma and urine. Bioconjug. Chem. 2009, 20, 913-923.
31. Preianò, M., Pasqua, L., Gallelli, L., Galasso, O. et al., Simultaneous extraction and rapid visualization of peptidomic and lipidomic body fluids fingerprints using mesoporous aluminosilicate and MALDI-TOF MS. Proteomics 2012, 12, 3286-3294.
32. Terracciano, R., Migliaccio, V., Savino, R., Pujia, A., Montalcini, T., Association between low bone mineral density and increate α-defensin in salivary fluid among postmenopausal women. Menopause 2013, 20, 1275-1279.
33. Bartlett, J. A., Albertolle, M. E., Wohlford-Lenane, C., Pezzulo, A. A. et al., Protein composition of bronchoalveolar lavage fluid and airway surface liquid from newborn pigs. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013, 305, 256-266.
34. Franciosi, L., Govorukhina, N., Ten Hacken, N., Postma, D., Bischoff, R., in: Toms, S. A., Weil, R. J. (Eds.), Nanoproteomics: Methods and Protocols, Methods in Molecular Biology, Springer, Heidelberg, London, New York 2011, pp. 17-28.
35. Franciosi, L., Govorukhina, N., Fusetti, F., Poolman, B. et al., Proteomic analysis of human epithelial lining fluid by microfluidics-based nanoLC-MS/MS: a feasibility study. Electrophoresis 2013, 34, 2683-2694.
36. Franciosi, L., Postma, D. S., van den Berge, M., Govorukhina, N. et al., Susceptibility to COPD: differential proteomic profiling after acute smoking. PLoS One 2014, 9. doi:10.1371/journal.pone.0102037.
37. Denlinger, L. C., Kelly, E. A., Dodge, A. M., McCartney, J. G. et al., Safety of and cellular response to segmental bronchoprovocation in allergic asthma. PLoS One 2013, 8, e51963.
38. Brennan, S., Gangell, C., Wainwright, C., Sly, P. D., Disease surveillance using bronchoalveolar lavage. Paediatr. Respir. Rev. 2008, 9, 151-159.
39. Dransfield, M. T., Garver, R. I., Weill, D., Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. J. Heart Lung Transplant. 2004, 23, 110-114.
40. Meyer, K. C., Raghu, G., Baughman, R. P., Brown, K. K. et al., An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit. Care Med. 2012, 185, 1004-1014.
41. Merkel, D., Rist, W., Seither, P., Weith, A., Lenter, M. C., Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005, 11, 2972-2980.
42. Kipnis, E., Hansen, K., Sawa, T., Moriyama, K. et al., Proteomic analysis of undiluted lung epithelial lining fluid. Chest 2008, 134, 338-345.
43. Magi, B., Bargagli, E., Bini, L., Rottoli, P. et al., Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics 2006, 6, 6354-6369.
44. Wattiez, R., Falmagne, P., Proteomics of bronchoalveolar lavage fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 815, 169-178.
45. Noël-Georis, I., Bernard, A., Falmagne, P., Wattiez, R., Proteomics as the tool to search for lung disease markers in bronchoalveolar lavage. Dis. Markers 2001, 17, 271-284.
46. Meyer, K. C., Raghu, G., Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful?. Eur. Respir. J. 2011, 38, 761-769.
47. Govender, P., Dunn, M. J., Donnelly, S. C, Proteomics and the lung: analysis of bronchoalveolar lavage fluid. Proteomics Clin. Appl. 2009, 3, 1044-1051.
48. Wheelock, C. E., Goss, V. M., Balgoma, D., Nicholas, B., Application of 'omics technologies to biomarker discovery in inflammatory lung diseases. Eur. Respir. J. 2013, 42, 802-825.
49. Wu, J., Kobayashi, M., Sousa, E. A., Liu, W. et al., Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Mol. Cell. Proteomics 2005, 4, 1251-1264.
50. Julius, P., Lommatzsch, M., Kuepper, M., Bratke, K. et al., Safety of segmental allergen challenge in human allergic asthma. J. Allergy Clin. Immunol. 2008, 121, 712-717.
51. Plymoth, A., Löfdahl, C. G., Ekberg-Jansson, A., Dahlbäck, M. et al., Human bronchoalveolar lavage: biofluid analysis with special emphasis on sample preparation. Proteomics 2003, 3, 962-972.
52. Nocker, R. E., van der Zee, J. S., Weller, F. R., van Overveld, F. J. et al., Segmental allergen challenge induces plasma protein leakage into the airways of asthmatic subjects at 4 hours but not at 5 minutes after challenge. J. Lab. Clin. Med. 1999, 134, 74-82.
53. Cederfur, C., Malmström, J., Nihlberg, K., Block, M. et al., Glycoproteomic identification of galectin-3 and -8 ligands in bronchoalveolar lavage of mild asthmatics and healthy subjects. Biochim. Biophys. Acta 2012, 1820, 1429-1436.
54. Zuberi, R. I., Hsu, D. K., Kalayci, O., Chen, H. Y. et al., Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am. J. Pathol. 2004, 165, 2045-2053.
55. Ge, X. N., Bahaie, N. S., Kang, B. N., Hosseinkhani, M. R. et al. Allergen-induced airway remodeling is impaired in galectin-3-deficient mice. J. Immunol. 2010, 185, 1205-1214.
56. Fu, X., Gharib, S. A., Green, P. S., Aitken, M. L., Spectral index for assessment of differential protein expression in shotgun proteomics. J. Proteome Res. 2008, 7, 845-854.
57. Mueller, L. N., Brusniak, M. Y., Mani, D. R., Aebersold, R., An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. J. Proteome Res. 2008, 7, 51-61.
58. Giorgianni, F., Mileo, V., Desiderio, D. M., Catinella, S. et al., Characterization of the phosphoproteome in human bronchoalveolar lavage fluid. Int. J. Proteomics 2012, 2012, 460261.
59. Casado, B., Iadarola, P., Luisetti, M., Kussmann, M., Proteomics-based diagnosis of chronic obstructive pulmonary disease: the hunt for new markers. Expert Rev. Proteomics 2008, 5, 693-704.
60. Plymoth, A., Löfdahl, C. G., Ekberg-Jansson, A., Dahlbäck, M. et al., Protein expression patterns associated with progression of chronic obstructive pulmonary disease in bronchoalveolar lavage of smokers. Clin. Chem. 2007, 53, 636-644.
61. Pastor, M. D., Nogal, A., Molina-Pinelo, S., Meléndez, R. et al., Identification of proteomic signatures associated with lung cancer and COPD. J. Proteomics 2013, 89, 227-237.
62. Tu, C., Mammen, M. J., Li, J., Shen, X. et al., Large-scale, ion-current-based proteomics investigation of bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patients. J. Proteome Res. 2014, 13, 627-639.
63. Nilsson, T., Mann, M., Aebersold, R., Yates, J. R., 3rd et al., Mass spectrometry in high-throughput proteomics: ready for the big time. Nat. Methods 2010, 7, 681-685.
64. Oda, Y., Huang, K., Cross, F. R., Cowburn, D. et al., Accurate quantitation of protein expression and site-specific phosphorylation. Proc. Natl. Acad. Sci. 1999, 96, 6591-6596.
65. Ryu, S., Gallis, B., Goo, Y. A., Shaffer, S. A. et al., Comparison of a label-free quantitative proteomic method based on peptide ion current area to the isotope coded affinity tag method. Cancer Inform. 2008, 6, 243-255.
66. Mutlu, G. M., Garey, K.W., Robbins, R. A., Danziger, L. H., Rubinstein, I., Collection and analysis of exhaled breath condensate in humans. Am. J. Respir. Crit. Care Med. 2001, 164, 731-737.
67. Bloemen, K., Hooyberghs, J., Desager, K., Witters, E., Schoeters, G., Non-invasive biomarker sampling and analysis of the exhaled breath proteome. Proteomics Clin. Appl. 2009, 3, 498-504.
68. Wiktorowicz, J. E., Jamaluddin, M., Proteomic analysis of the asthmatic airway. Adv. Exp. Med. Biol. 2014, 795, 221-232.
69. Bloemen, K., Van Den Heuvel, R., Govarts, E., Hooyberghs, J. et al., A new approach to study exhaled proteins as potential biomarkers for asthma. Clin. Exp. Allergy 2011, 41, 346-356.
70. Fumagalli, M., Dolcini, L., Sala, A., Stolk, J. et al., Proteomic analysis of exhaled breath condensate from single patients with pulmonary emphysema associated to α1-antitrypsin deficiency. J. Proteomics 2008, 71, 211-221.
71. Fumagalli, M., Ferrari, F., Luisetti, M., Stolk, J. et al., Profiling the proteome of exhaled breath condensate in healthy smokers and COPD patients by LC-MS/MS. Int. J. Mol. Sci. 2012, 13, 13894-13910.
72. Savino, R., Paduano, S., Preianò, M., Terracciano, R., The proteomics big challenge for biomarkers and new drug-targets discovery. Int. J. Mol. Sci. 2012, 13, 13926-13948.
73. Zhang, X., Leung, S. M., Morris, C. R., Shigenaga, M. K., Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J. Biomol. Tech. 2004, 15, 167-175.
74. Murphy, V. E., Johnson, R. F., Wang, Y. C., Akinsanya, K. et al., Proteomic study of plasma proteins in pregnant women with asthma. Respirology 2006, 11, 41-48.
75. Nishioka, T., Uchida, K., Meno, K., Ishii, T. et al., Alpha-1-antitrypsin and complement component C7 are involved in asthma exacerbation. Proteomics Clin. Appl. 2008, 2, 46-54.
76. Rhim, T., Choi, Y. S., Nam, B. Y., Uh, S. T. et al., Plasma protein profiles in early asthmatic responses to inhalation allergen challenge. Allergy 2009, 64, 47-54.
77. Park, C. S., Rhim, T., Application of proteomics in asthma research. Expert Rev. Proteomics 2011, 8, 221-230.
78. Singh, A., Cohen Freue, G. V., Oosthuizen, J. L., Kam, S. H. et al., Plasma proteomics can discriminate isolated early from dual responses in asthmatic individuals undergoing an allergen inhalation challenge. Proteomics Clin. Appl. 2012, 6, 476-485.
79. Izbicka, E., Streeper, R. T., Michalek, J. E., Louden, C. L. et al., Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics 2012, 9, 27-35.
80. Gomes-Alves, P., Imrie, M., Gray, R. D., Nogueira, P. et al., SELDI-TOF biomarker signatures for cystic fibrosis, asthma and chronic obstructive pulmonary disease. Clin. Biochem. 2010, 43, 168-177.
81. Verrills, N. M., Irwin, J. A., He, X. Y., Wood, L. G. et al., Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011, 183, 1633-1643.
82. Pinto-Plata, V., Toso, J., Lee, K., Bilello, J. et al., Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc. Am. Thorac. Soc. 2006, 3, 465-466.
83. Bozinovski, S., Hutchinson, A., Thompson, M., Macgregor, L. et al., Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008, 177, 269-278.
84. Rana, G. S., York, T. P., Edmiston, J. S., Zedler, B. K. et al., Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette smokers with chronic obstructive pulmonary disease (COPD). Anal. Bioanal. Chem. 2010, 397, 1809-1819.
85. Bandow, J. E., Baker, J. D., Berth, M., Painter, C. et al., Improved image analysis workflow for 2-D gels enables large-scale 2-D gel-based proteomics studies-COPD biomarker discovery study. Proteomics 2008, 8, 3030-3041.
86. Merali, S., Barrero, C. A., Bowler, R. P., Chen, D. E. et al., Analysis of the plasma proteome in COPD: novel low abundance proteins reflect the severity of lung remodeling. COPD 2014, 11, 177-189.
87. Lindhal, M., Stahlbom, B., Tagesson, C., Two-dimensional gel electrophoresis of nasal and bronchoalveolar lavage fluids after occupational exposure. Electrophoresis 1995, 16, 1199-1204.
88. Benson, L. M., Mason, C. J., Friedman, O., Kita, H. et al., Extensive fractionation and identification of proteins within nasal lavage fluids from allergic rhinitis and asthmatic chronic rhinosinusitis patients. J. Sep. Sci. 2009, 32, 44-56.
89. Bons, J. A., Wodzig, W. K., van Dieijen-Visser, M. P., Protein profiling as a diagnostic tool in clinical chemistry: a review. Clin. Chem. Lab. Med. 2005, 43, 1281-1290.
90. Albrethsen, J., Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 2007, 53, 852-858.
91. Preianò, M., Falcone, D., Maggisano, G., Montalcini, T. et al., Assessment of pre-analytical and analytical variables affecting peptidome profiling of gingival crevicular fluid by MALDI-TOF mass spectrometry. Clin. Chim. Acta 2014, 437, 120-128.
92. Rosias, P. P., Robroeks, C. M., Niemarkt, H. J., Kester, A. D. et al., Breath condenser coatings affect measurement of biomarkers in exhaled breath condensate. Eur. Respir. J. 2006, 28, 1036-1041.
93. Silkoff, P. E., Erzurum, S. C., Lundberg, J. O., George, S. C. et al., ATS workshop proceedings: exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate. Proc. Am. Thorac. Soc. 2006, 3, 131-145.
94. Stockley, R. A., Biomarkers in chronic obstructive pulmonary disease: confusing or useful?. Int. J. Chron. Obstruct. Pulmon. Dis. 2014, 9, 163-177.
95. Fehrani, N., Letuve, S., Kozhich, A., Thibaudeau, O. et al., Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010, 181, 917-927.
96. Ohlmeier, S., Vuolanto, M., Toljamo, T., Vuopala, K. et al., Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J. Proteome Res. 2008, 7, 5125-5132.
97. Mazur, W., Toljamo, T., Ohlmeier, S., Vuopala, K. et al., Elevation of surfactant protein A in plasma and sputum in cigarette smokers. Eur. Respir. J. 2011, 38, 277-284.
98. Miniati, M., Monti, S., Basta, G., Cocci, F. et al., Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic corpulmonale: a case-control study. Respir. Res. 2011, 12, 37.
99. Smith, D. J., Yerkovich, S. T., Towers, M. A., Carroll, M. L. et al., Reduced soluble receptor for advanced glycation end-products in COPD. Eur. Respir. J. 2011, 37, 516-522.
100. Ilumets, H., Mazur, W., Toljamo, T., Louhelainen, N. et al., Ageing and smoking contribute to plasma surfactant proteins and protease imbalance with correlations to airway obstruction. BMC Pulm. Med. 2011, 19, 11-19.
101. Savino, R., Terracciano, R., Mesopore-assisted profiling strategies in clinical proteomics for drug/target discovery. Drug Discov. Today 2012, 17, 143-152.
102. Auffray, C., Adcock, I. M., Chung, K. F., Djukanovic, R. et al., An integrative systems biology approach to understanding pulmonary diseases. Chest 2010, 137, 1410-1416.
103. Nicholas, B. L., O'Connor, C. D., Djukanovic, R., From proteomics to prescription-the search for COPD biomarkers. COPD 2009, 6, 298-303.